UGT1A1 Gene Polymorphism TA Repeat

This test measures a specific gene variation - UGT1A1 Gene Polymorphism TA Repeat that affects how the body processes certain medications, such as irinotecan used for GI malignancies

This test is done for the following reasons:

• Predict Drug Response: The UGT1A1 gene polymorphism test is conducted to predict an individual's response to medications metabolized by the UDP-glucuronosyltransferase 1A1 enzyme, such as irinotecan and certain drugs for hyperbilirubinemia.

• Identify Genetic Variations: It helps identify genetic variations in the UGT1A1 gene, particularly in the TA repeat region, which can influence enzyme activity and drug metabolism.

• Personalize Medication Regimens: By understanding a patient's genetic profile, healthcare providers can tailor medication regimens, adjusting dosages or selecting alternative medications to optimize therapeutic outcomes and minimize adverse effects.

• Minimize Adverse Drug Reactions: The test aids in minimizing the risk of adverse drug reactions associated with medications metabolized by UGT1A1, particularly in individuals with reduced enzyme activity due to specific genetic variants.

• Enhance Precision Medicine: It contributes to the advancement of precision medicine by integrating genetic information into clinical decision-making, allowing for more individualized and effective treatment approaches.

• Improve Patient Safety: By incorporating genetic testing, healthcare providers can enhance patient safety by mitigating the potential for adverse drug reactions and optimizing medication management based on individual genetic characteristics.

• Guide Clinical Decision-Making: Results from the UGT1A1 gene polymorphism test provide valuable guidance for clinicians in selecting appropriate medications and dosages, thereby improving therapeutic outcomes and overall patient care.

This test is recommended in the following situations:

• Patients requiring treatment with irinotecan for GI malignancies.
• Patients with a suspected or confirmed diagnosis of Gilbert Syndrome.
• Individuals with a family history of Gilbert Syndrome or drug-related toxicities.

If the UGT1A1 Gene Polymorphism test results are abnormal, it may indicate an increased risk of toxic reactions to drugs like irinotecan or confirm the presence of Gilbert Syndrome. It is important to discuss the results with your doctor.

• A small sample of your blood will be collected.
• The sample will be sent to the laboratory for analysis.
• The laboratory will use a method called Sequencing to determine your genetic variation.

• No specific preparation is required.
• Follow any instructions provided by your doctor regarding fasting or avoiding certain substances before the test.

• Liver Function Tests: These tests help assess the overall function and health of the liver.
• Complete Blood Count: This test provides information about different types of blood cells and can detect any abnormalities.
• Comprehensive Metabolic Panel: This panel of tests evaluates kidney and liver function, as well as electrolyte levels.

Gilbert Syndrome Confirmation Test

Gilbert Syndrome is a common genetic disorder characterised by high levels of bilirubin in the blood. It is usually harmless and does not require treatment. People with Gilbert Syndrome may have no symptoms or experience occasional episodes of mild jaundice during times of stress, illness, or fasting.

Pharmacogenomics is the study of how an individual's genetic makeup influences their response to drugs. It involves analyzing how variations in genes can affect drug metabolism, efficacy, and potential adverse effects. By understanding these genetic differences, pharmacogenomics aims to personalize medication regimens, optimize dosages, and improve therapeutic outcomes while minimizing the risk of adverse reactions. This field combines principles from pharmacology and genomics to develop tailored treatment strategies, ultimately advancing precision medicine and enhancing patient care. Pharmacogenomic testing can help healthcare providers make informed decisions about drug selection and dosing, leading to more effective and safer treatments for individuals based on their unique genetic profiles.